(WSVN) - The US Food and Drug Administration (FDA) is fast tracking an experimental COVID-19 treatment.
The drug, RLF-100, is currently being studied at the University of Miami Miller School of Medicine.
It was previously only being given to coronavirus patients already on a ventilator.
RLF-100 is said to work by blocking COVID-19 from attaching to the lungs.
Under the new fast track protocol, the FDA will allow doctors to request an inhaled version of the drug.
RLF-100 would be used on patients with COVID-19 related breathing problems prior to using a ventilator.
The drug’s manufacturers, NeuroRx and Relief Therapeutics, will be submitting the treatment plan for FDA approval.
Copyright 2022 Sunbeam Television Corp. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.